These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36987666)

  • 1. Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reforms.
    Quinn C; Ciarametaro M; Sils B; Phares S; Trusheim MR
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):535-546. PubMed ID: 36987666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicaid best price reforms to enable innovative payment models for cell and gene therapies.
    Quinn C; Ciarametaro M; Sils B; Phares S; Trusheim M
    Expert Rev Pharmacoecon Outcomes Res; 2023 Feb; 23(2):191-203. PubMed ID: 36579425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in Medicaid Rebates Paid by Pharmaceutical Manufacturers for Outpatient Infused, Injected, Implanted, Inhaled, or Instilled Drugs: The 5i Loophole.
    Dickson S; Gabriel N; Gellad W; Hernandez I
    J Health Polit Policy Law; 2022 Dec; 47(6):835-851. PubMed ID: 35867551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experiences and Interest in Value-Based Payment Arrangements for Medical Products Among Medicaid Agencies: An Exploratory Analysis.
    Bhuiyan Khan B; Gemme V; Chupp E; Higgins A; Sorenson C
    Milbank Q; 2024 Jun; ():. PubMed ID: 38847241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
    Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
    J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicaid program; time limitation on price recalculations and recordkeeping requirements under the drug rebate program. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Aug; 68(168):51912-7. PubMed ID: 12962118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act.
    Bonakdar Tehrani A; Carroll NV
    Appl Health Econ Health Policy; 2017 Aug; 15(4):513-520. PubMed ID: 28224469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
    Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
    JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving Medicaid Coverage Policy and Rebates.
    Ohn JA; Kaltenboeck A
    AMA J Ethics; 2019 Aug; 21(8):E645-653. PubMed ID: 31397659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians.
    Bachhuber MA
    Addict Sci Clin Pract; 2020 Jun; 15(1):20. PubMed ID: 32600402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicaid Spending on Antiretrovirals From 2007 Through 2019.
    Walsh BS; Kesselheim AS; Rome BN
    Clin Infect Dis; 2023 Mar; 76(5):833-841. PubMed ID: 36268585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel imports under a manufacturer rebate and a price freeze: Evidence from Germany.
    Birg L
    Health Econ; 2023 Feb; 32(2):302-323. PubMed ID: 36336829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assistive technology pricing in Australia: is it efficient and equitable?
    Summers MP; Verikios G
    Aust Health Rev; 2018 Feb; 42(1):100-110. PubMed ID: 28160784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.
    Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State strategies to address medicaid prescription spending: negotiated pricing vs price transparency.
    Noh S; Janousek CL; Park JH
    Health Econ Policy Law; 2021 Apr; 16(2):201-215. PubMed ID: 32349843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
    Seay M; Varma P
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
    Mattingly TJ; Levy JF; Slejko JF; Onwudiwe NC; Perfetto EM
    Pharmacoeconomics; 2018 Sep; 36(9):1093-1099. PubMed ID: 29752675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and impact of bundled payment for detox and follow-up care.
    Quinn AE; Hodgkin D; Perloff JN; Stewart MT; Brolin M; Lane N; Horgan CM
    J Subst Abuse Treat; 2017 Nov; 82():113-121. PubMed ID: 29021109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.